Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin
, 2
Abstract
Introduction: Asprosin is a hormone that was first reported by Romere et al. [2016]. Its secretion is induced in the case of starvation. Asprosin promotes hepatic glucose release. There is no literature information available in humans to demonstrate how blood and saliva asprosin levels of patients with the newly identified type 2 diabetes mellitus (T2DM) changed after metformin treatment. We aim to examine these changes and contribute to the literature in this sense.
Material and methods: A total of 60 individuals: 30 healthy volunteers and 30 newly identified cases of T2DM whose treatment had been initiated, were included in the investigation. Blood and saliva sample specimens were carefully taken from both groups. Saliva asprosin and serum levels were tested using the ELISA method. Immunohistochemical methods were used to test asprosin formation sites in salivary gland tissues.
Results: Similarly increased asprosin levels were observed in patients from the newly diagnosed T2DM group compared with the healthy control group (p = 0.003). In the newly defined T2DM group, blood asprosin levels decreased significantly after three months of metformin treatment (p = 0.032). In terms of saliva asprosin levels, when the healthy control group and the newly identified T2DM group were compared, saliva asprosin levels were found to be higher in the newly identified T2DM group (p < 0.001). With immunohistochemical staining, asprosin immunoreactivity was observed in the submandibular and parotid glands.
Conclusions: In our study, serum and saliva asprosin levels increased significantly in the newly identified individuals with type 2 diabetes, which suggests that asprosin could form a critical risk related to T2DM. Higher asprosin levels are an important marker for predicting diabetes development, and that this hormone can be signified as a main or target molecule in the treatment of diabetes.
Keywords: type 2 diabetes mellitusasprosinmetformin
References
- Wang CCi, Shah ACC. (eds). Medical Management of Type 1 Diabetes. 7th ed. American Diabetes Association, Alexandria 2017.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 Suppl 1: S81–S90.
- Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157: 107843.
- Zhou T, Xu X, Du M, et al. A preclinical overview of metformin for the treatment of type 2 diabetes. Biomed Pharmacother. 2018; 106: 1227–1235.
- Baron AD, Schaeffer L, Shragg P, et al. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987; 36(3): 274–283.
- Molina Vega M, Muñoz-Garach A, Tinahones FJ. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2018; 14(2): 207–217.
- Davies MJ, D'Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669–2701.
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2019; 42(Suppl 1): S90–S9S102.
- Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016; 165(3): 566–579.
- Greenhill C. Liver: Asprosin — new hormone involved in hepatic glucose release. Nat Rev Endocrinol. 2016; 12(6): 312.
- Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019; 489: 183–188.
- Gillett MJ, Kilpatrick ES, Bloomgarden ZT, et al. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32(7): 1327–1334.
- Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015; 72: 4–15.
- Kajimura S. Adipose tissue in 2016: Advances in the understanding of adipose tissue biology. Nat Rev Endocrinol. 2017; 13(2): 69–70.
- Lee T, Yun S, Jeong JiH, et al. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019; 486: 96–104.
- Ugur K, Aydin S. Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. Int J Endocrinol. 2019; 2019: 2521096.
- Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013; 19(12): 1649–1654.
- Shaw RJ. Metformin trims fats to restore insulin sensitivity. Nat Med. 2013; 19(12): 1570–1572.
- Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310(5754): 1642–1646.
- Tang C, Naassan A, Chamson-Reig A, et al. Susceptibility to Fatty Acid-Induced β-Cell Dysfunction Is Enhanced in Prediabetic Diabetes-Prone BioBreeding Rats: A Potential Link Between β-Cell Lipotoxicity and Islet Inflammation. Endocrinology. 2013; 154(1): 89–101.
- Zhang X, Jiang H, Ma X, et al. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2020; 11(2): 349–355.
- Wang CY, Lin TA, Liu KH, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes (Lond). 2019; 43(5): 1019–1025.
